hailed etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
hailed etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

3 Haziran 2014 Salı

New skin cancer drug hailed "paradigm shift" in therapy

Advanced skin cancer, which has spread to other components of the entire body, has a bad prognosis and currently only 1 in 10 individuals dwell for a yr after diagnosis.


However some men and women have lived for two many years although getting the new therapy.


The new drug is being evaluated for use in 30 varieties of cancer.


The review, presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2014), showed 3 quarters of sufferers responded to the drug.


The drug is an antibody that enables the body’s immune system to as soon as again ‘see’ the cancer as a foreign invader and so attack it.


Numerous businesses have begun producing similar medication and have been testing them in a selection of cancers.


A single known as ipilimumab (Yervoy) is presently on the market place for advanced malignant melanoma and can improve regular survival from six months to ten months when in contrast with common treatment.


The new drug was found to increase survival in those sufferers whose cancer had started out increasing once more following treatment with ipilimumab.


Gillian Nuttall, Founder of Melanoma Uk explained: “Advanced melanoma is a horrible disease with a bad prognosis.


“Pembrolizumab represents the most current advance in a whole raft of new treatments in superior melanoma which have come by way of above the past couple of many years.


“The pembrolizumab outcomes are really fascinating and could signify a turning point for sufferers affected by innovative melanoma giving them a greater likelihood of survival.”


The makers, MSD, are hoping to apply for a European licence by the end of the yr and it has been accepted for a rapidly-track licencing method in America.


Professor Peter Johnson, Cancer Study UK’s chief clinician, said: “It’s interesting to see the variety of new therapies that are emerging for individuals with innovative melanoma. These new therapies harness the body’s own immune system to fight this cancer that has previously been so difficult to treat properly.


“Melanoma can only grow by discovering a way to escape detection by the immune technique. One way it does this is by triggering a shut-off switch on immune cells when they get near to the tumour.


“This therapy blocks the cancer cells’ capacity to use this switch, permitting the immune technique to recognise and ruin the cancer. We are seeing a entire variety of these immune therapies coming into the clinic, primarily based upon the excellent progress we are making in our investigation into the immune program.”



New skin cancer drug hailed "paradigm shift" in therapy

14 Mayıs 2014 Çarşamba

AstraZeneca cancer drug hailed as "great white hope" in battle towards sickness

AstraZeneca

AstraZeneca’s head drug developer: This drug could “hold the prospective to form the future of cancer treatment”. Photograph: Christopher Furlong/Getty Photos




It might not be the catchiest of names, but AstraZeneca drug MEDI4736 was revealed on Wednesday night as a “new fantastic white hope” in the fight against cancer as it took centre stage in the British company’s battle against Pfizer’s planned £63bn takeover.


It is this drug, designed in Cambridge and Maryland, that AstraZeneca chief executive Pascal Soriot was referring to when he warned MPs that an aggressive cost-cutting transaction could delay improvement and price lives.


Physicians and scientists are so excited about the likely of MEDI4736 that it has been quickly-tracked to phase III hospital trials just before the outcomes of the initial clinical benefits have even be published.


AstraZeneca’s head drug developer Briggs Morrison believes the drug, which has initially been trialled on lung cancer but could be extended to a total range of tumours, could “hold the potential to shape the long term of cancer remedy” and rake in yearly sales of up to £3.9bn.


The benefits of phase-I trials were launched on Wednesday night ahead of a full presentation at the American Society of Clinical Oncology conference later this month.


The advancement of MEDI4736, or in scientific terms a human monoclonal antibody, is so critical to AstraZeneca that Soriot will fly to the ASCO conference in Chicago to oversees its presentation.


MEDI4736 performs by stripping cancer cells of their “stealth cloak” so that the patient’s immune technique can detect and destroy tumours, and could change chemotherapy in some cases. AstraZeneca last week began testing the drug on 702 patients that are suffering from non-tiny-cell lung carcinoma at a lot more than a hundred hospitals across the globe. The tests have begun far more than six months ahead of schedule as AstraZeneca rushes to get the drug to market ahead of rivals.


“MEDI4736 is an crucial molecule in our immuno-oncology portfolio and its entry into phase III clinical trials is more proof of our commitment to invest in distinctive science in our core therapy regions, and to rapidly progress our immuno-oncology pipeline,” Morrison said. “Lung cancer is still the major cancer killer, there is a clear need for a lot more treatment method possibilities to provide individuals with a greater possibility of beating the illness.”


The pleasure surrounding the drug was even more underpinned on Wednesday when the business announced plans for a separate trial of MEDI4736 in conjunction with yet another drug to develop “an enhanced anti-tumour immune response”.


Savvas Neophytou, analyst at Panmure Gordon, said the investment and scientific communities were buzzing with excitement about the “excellent white hope [of] MEDI4736″.


He mentioned combining MEDI4736 with US biotech organization Incyte’s NCB24360 molecule was the equivalent of “removing the stealth from cancer and hitting the target with significantly higher ballistics at the same time”.


“MEDI4736 blocks the signals that support tumours keep away from detection by the immune technique, countering the tumour’s immune-evading tactics, although INCB24360 enhances the potential of immune cells to combat the tumour,” he stated.


Colin White, lead analyst and head of oncology at Datamonitor Healthcare, mentioned MEDI4736 had “a incredible sum of commercial possible”.


“It looks like it truly is going to be an effective remedy against a wide selection of distinct tumours, so there is possible for higher industrial returns.


“This drug could be really worth multi-billions of dollars, but here there are lots of rivals out there and there is a chance they could get beat AstraZeneca to market and steal a enormous industrial benefit.”


Roche, Merck and Bristol-Myers are also creating similar immunotherapy therapies.


Regardless of AstraZeneca’s criticism of the positive aspects of massive pharmaceutical acquisitions in the wake of Pfizer’s curiosity, it picked up MEDI4736 when it purchased Maryland analysis firm MedImmune for $ 15.6bn (£9.3bn) in 2007. The business has developed a number of of AstraZeneca’s most promising pipeline drugs which includes other cancer immunology medicines Tremelimumab, MEDI0680 and MEDI6469.


If MEDI4736 proves as profitable as hoped it could be well worth about £35bn if it was spun out on its very own, according to analysts.


Soriot warned on Tuesday that a Pfizer takeover and the struggle to reconcile “saving tax and saving lives” could jeopardise the progress of medicines. “Any distraction on operate we are doing now could run the chance of delaying our drugs pipeline,” he mentioned, alluding to Pfizer’s wish to save US tax payments via taking above AstraZeneca and domiciling the mixed organization in the United kingdom. He additional: “From the lab to the patient takes several many years.”


There are fears that long term of MedImmune, in Gaithersburg, Maryland, could be particularly at risk because Pfizer has committed to basing at least twenty% of analysis and improvement employees in the Uk and the US business already has a 25-acre globe-major oncology analysis park in San Diego, California.


John LaMattina, Pfizer’s head of investigation from 2004-2007, said he would be anxious if he worked at MedImmune and pointed out that the business consolidated three oncology investigation internet sites into its La Jolla campus while he was in charge.


US politicians have written to Read to implore him to sustain MedIummune’s investigation in Gaithersburg if the deal goes ahead.


Maryland congressman John Delaney mentioned Read’s promises to preserve 1 fifth of the mixed company’s investigation in the United kingdom made him fret that it would “put much more strain on choices they make in the US”.


Soriot has accused Pfizer of making an attempt to snap up AstraZeneca on the cheap just before the accurate worth of its long term medicines are reflected in its share price.


“A year and a half ago, we did not have significantly of a portfolio,” he explained. “Now we have one particular of the best in the market.”


Roy Herbst, chief of medical oncology at the Yale Cancer Center, stated: “Each and every company is realising that immune therapy is going to be element of armamentarium [doctor"s arsenal towards] nearly every single cancer.”


He mentioned acquiring AstraZeneca would give Pfizer “all the immune treatment they will not have. They absolutely want to spouse.”




AstraZeneca cancer drug hailed as "great white hope" in battle towards sickness

8 Ocak 2014 Çarşamba

Ethiopia"s model families hailed as agents of social transformation

Wudinesh Demisse raises her hand over her head, displaying off the matchstick-sized birth-management implant embedded just beneath the skin of her upper arm.


Demisse, 28, is a farmer in rural West Arsi, in Ethiopia’s central Oromia area. With 3 kids already, Demisse says it is time to cease. “For me, 3 is enough,” she says, through a translator. “If they are too a lot of, they are too high-priced.”


Demisse, who lives in a tiny village 200km south of the capital, Addis Ababa, is one particular of hundreds of thousands of Ethiopian ladies who have gained accessibility to modern day forms of birth handle above the previous decade. These days, her local well being publish stocks a range of items, from condoms and pills to longer-acting injections and implants.


Ethiopia is more and more touted as a household planning success story. The government, which has made maternal and child wellness national priorities, is proud of its statistics – the country’s contraceptive prevalence fee, for instance, jumped from 15% in 2005 to 29% in 2011 – and says efforts to attain remote, rural locations lie at the heart of its accomplishment.


Along with skilled, salaried overall health extension staff – all of whom are female, a stage to make families much more comfy with door-to-door visits – thousands of volunteers have been enlisted nationwide in the government’s “well being growth army”.


At the centre of this are men and women like Demisse and her husband, who head a single of the government’s celebrated “model households” and are footsoldiers in a substantial social engineering venture to redefine healthy behaviour.


“They are role designs and adjust agents for social transformation in every single village across the country,” says Kesetebirhan Admasu, Ethiopia’s wellness minister, who explains that the venture is based on a theory of how innovations spread that assumes alter takes place step by step. The thought is that there are “trendsetters” in every single neighborhood, and that other individuals can be persuaded to admire and, at some point, copy their behaviour.


To turn into a model loved ones, a family has to adopt most if not all of the government’s sixteen priority interventions – from vaccinating their children and sleeping below mosquito bednets to building separate latrines and employing family preparing.


Model families get certificates, are celebrated at village ceremonies and are asked to support five other households in adopting the priority interventions.


Ethiopia, Africa’s 2nd most populous country, is overwhelmingly rural and this has hampered the growth of formal healthcare companies and infrastructure. Estimates from 2009 recommend there was only a single medical doctor for each and every 50,000 individuals. The government’s health extension programme is a strategy to bridge the gap and develop capacity even though expanding the solutions.


The NGO Marie Stopes Global has urged wealthy countries to adopt some of Ethiopia’s methods, saying they could save hundreds of thousands of bucks if they too trained up frontline well being staff, nurses and midwives to carry out duties – this kind of as the fitting of implants – otherwise completed by doctors.


For Admasu, the largest successes have come from focusing on “cultural and perspective-related bottlenecks”, which restrict rural girls from taking up solutions even when they are accessible.


In one region, Admasu says the overall health development army assisted the government understand why females were not giving birth in wellness amenities. The army found girls were fearful of the conventional stretchers used to carry them to hospital (which had turn into connected with bad luck) and did not want to go with out the traditional coffee and religious ceremonies they could get at house. This led to changes such as a newly-designed stretcher and plans to bring coffee beans, standard food, and religious leaders to wellness services.


“All these innovations and interventions, they look to be straightforward but it is altering the way companies are perceived,” Admasu says. In the situation of household preparing, he says merchandise like implants were not common just before but are now being utilised by a significant amount of rural ladies. “It’s all due to the fact of the data that they get from their neighbours, from their close friends and so on,” he says. “That is how they break all people cultural norms.”


A lot of African nations have set up comprehensive neighborhood healthworker schemes to attain rural places. Comprehending why people behave the way they do, and structuring projects accordingly, is also an more and more well-known approach in development, and a response to the failures of several skilled-led schemes. The World Financial institution, for example, is doing work on a significant report on the behavioural and social foundations of economic development, anticipated this 12 months.


The military metaphors in Ethiopia’s programme set it apart from several others, nevertheless. “Such a motion would not be profitable with no the discipline of the army,” insists Admasu. “We said this is the way we really want to mobilise the community – they participate in the meetings, they function with the discipline of an army, and they tackle the essential bottlenecks.”


Admasu says it is the government’s policy to guarantee girls are not coerced into taking up wellness interventions. But some are suspicious of the growth army model, which is also becoming pursued in agriculture with a nationwide network of “model farmers”.


Ethiopian journalist Henok Reta has reported, for example, that model farmers who boast of their outcomes look to have been coached by extension staff and are unwilling to speak about failures, difficulties such as the value of seeds, and what they want the government to do subsequent. A recent paper from the Overseas Advancement Institute thinktank in London notes that local community mobilisation efforts in Ethiopia, such as the advancement army, can supply the ruling party with new mechanisms to monitor its citizens.


Teferi Abate Adem, former chairman of the division of sociology and anthropology at Addis Ababa University, argues that the agriculture extension programme has “reinforced the rural presence and authoritarian powers of the ruling celebration whilst largely failing to boost smallholder agriculture”.



Ethiopia"s model families hailed as agents of social transformation